Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Susanna Grzeschik"'
Autor:
Marco A. Zarbin, Susanna Grzeschik, Steven Francom, Philippe Margaron, Wayne Macfadden, Giovanni Staurenghi, Cornelia Dunger-Baldauf, Lisa Tuomi, Howard Snow, Alan F. Cruess, Zdenka Haskova
Publikováno v:
Ophthalmology Retina. 2:1087-1096
Topic This study evaluated the cardiovascular/cerebrovascular safety profile of ranibizumab 0.5 mg versus sham ± verteporfin in patients with neovascular age-related macular degeneration (nAMD). In addition, comparisons of ranibizumab 0.3 mg with sh
Autor:
Jason S. Ehrlich, Aaron Osborne, Sunil S. Patel, Susanna Grzeschik, Philip J. Ferrone, Arshad M. Khanani, Zdenka Haskova, Karen Basu, Jayashree Sahni, Pravin U. Dugel
Publikováno v:
JAMA Ophthalmol
Importance Faricimab neutralizes angiopoietin-2 and vascular endothelial growth factor A via both simultaneous and independent binding. Objective To evaluate extended dosing with faricimab, the first bispecific antibody designed for intraocular use,
Autor:
Ronald A. Cantrell, Natasha Singh, Steven Francom, Susanna Grzeschik, Pravin U. Dugel, Anne E. Fung
Publikováno v:
Ophthalmology. Retina. 2(7)
Ranibizumab safety is well established for treatment of neovascular age-related macular degeneration (nAMD), but less is known about the risk of systemic serious adverse events (SAEs), specifically among patients with heightened baseline risk due to
Autor:
C. Zerbini, Jennifer Green, Ewa Olech, Wolfgang Dummer, Ali Ashrafzadeh, Susanna Grzeschik, Rebecca Bieraugel, William Stohl, Jean Dudler, Juan J. Gomez-Reino, Steven Francom, Roy Fleischmann
Publikováno v:
Annals of the Rheumatic Diseases
Objective To determine the efficacy and safety of ocrelizumab (OCR) with methotrexate (MTX) in MTX-naive rheumatoid arthritis (RA) patients. Methods In a randomised, double-blind, controlled trial, patients received placebo+MTX (MTX; n=210), OCR 200
Autor:
Neil Inhaber, Susanna Grzeschik, Neil T. Feldman, Teresa L. Steininger, Yanping Zheng, Charles F. P. George, Chinglin Lai
Publikováno v:
Sleepbreathing = SchlafAtmung. 15(1)
Sodium oxybate (SXB) is approved for cataplexy and excessive daytime sleepiness in narcolepsy. Obstructive sleep apnea syndrome (OSAS) affects ∼9-50% of narcoleptics. Effects of 2-week SXB administration on apnea-hypopnea index (AHI), oxygen satura
Autor:
Charles F. P. George, Chinglin Lai, Teresa L. Steininger, Neil Inhaber, Susanna Grzeschik, Neil T. Feldman, Yanping Zheng
Publikováno v:
Sleep medicine. 11(1)
Objective Sodium oxybate (SXB) is an approved drug for the treatment of excessive daytime sleepiness (EDS) and cataplexy in narcolepsy. Obstructive sleep apnea syndrome (OSAS) is a condition that frequently co-occurs with narcolepsy. Given the known
Autor:
Josef Krieglstein, Yuan Zhu, Susanne Klumpp, Susanna Grzeschik, Barbara Ahlemeyer, Stephanie Schwarz
Publikováno v:
Neurochemistry international. 46(2)
There is increasing evidence showing the involvement of unsaturated free fatty acids in cell death pathways, particularly in the context of apoptotic signalling. Our previous in vitro study has demonstrated that oleic acid, a monounsaturated fatty ac
Autor:
M. Keiserman, N. Mitchell, Susanna Grzeschik, Sophie Dimonaco, G.-R. Burmester, W. Rigby, R. van Vollenhoven, Ricardo Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 73:672.1-672
Background Treatment with TCZ in combination with MTX or as monotherapy in MTX-naive patients (pts) with early RA previously demonstrated improvements in signs and symptoms and in inhibition of structural joint damage in all treatment groups at 52 wk